Cordlife's 'belle of the ball' in bid for China Cord Blood
Takeover bid for US-listed China Cord Blood Corp shines spotlight on its substantial shareholder Singapore's Cordlife
Add BT as a preferred source
DeeperDive is a beta AI feature. Refer to full articles for the facts.
Singapore
A TAKEOUT offer for a major China cord blood firm listed on the New York Stock Exchange is firing up interest in its substantial shareholder Singapore-listed Cordlife Group with expectations that it too may be a target in the bid to control China Cord Blood Corp (CCBC).
On Monday, CCBC said that it received a non-binding cash offer from its 42 per cent owner Golden Meditech (GM) for US$6.40 per share, ending weeks of speculation of a possible privatisation bid. (Golden Meditech is 27 per cent owned by CCBC chairman Kam Yuen).
Copyright SPH Media. All rights reserved.
